We believe ChemoCentryx has established the broadest pipeline of novel drugs targeting chemokine and chemoattractant receptors in the pharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage small molecule compounds, each targeting a distinct chemokine or chemoattractant receptor. Our compounds are designed to be highly potent, selective to minimize the risk of off-target effects and orally-available for improved patient compliance. As small molecules, they are also easier and less costly to manufacture than protein therapeutics, or biologics.
We currently have five drug candidates in clinical development. Our pipeline comprises the following programs:
- CCX168 - Targeting the chemoattractant receptor known as C5aR (which binds the complement fragment C5a), CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV (also referred to ANCA-associated glomerulonephritis, or AAGN); A Phase IIa clinical trial with CCX168 in aHUS and IgAN are expected to start in H1 2015;
- CCX140 - Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Data from an ongoing 52-week clinical trial in 332 patients were reported in the fourth quarter of 2014. The primary and secondary end points were met;
- CCX872 - Our second generation orally administered inhibitor targeting CCR2, CCX872 completed Phase I clinical trial in 2014. A Phase Ib clinical trial with CCX872 in Pancreatic Cancer is expected to start in H1 2015;
- Vercirnon (also known as Traficet-EN, or CCX282) -Targeting the chemokine receptor known as CCR9, vercirnon is our drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. In September 2013, we regained all rights to this program from our former partner Glaxo Group Limited, or GSK, an affiliate of GlaxoSmithKline. and
- CCX507 - Our second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development in the first half of 2014.
We also have several additional drug candidates in the early stage programs that we are advancing through preclinical development:
Early Stage Programs in Immuno/Oncology and Autoimmune Diseases:
- " Chemokine Receptor Targets: CCR1, CCR4, CCR5, CCR6, CXCR6, CXCR7
^ Return to Top